PNS131 DO THE EVOLVING MARKET ACCESS POLICY DYNAMICS AND INCREASING IMPORTANCE OF CLINICAL AND HEALTH ECONOMIC EVIDENCE REPRESENT THE NEXT BIG OPPORTUNITY FOR PHARMA TO DEMONSTRATE VALUE IN CHINA?
Abstract
Authors
A. Wang M. Chalmers